Akari Therapeutics Plc — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
Akari amended employment agreement with CEO Abizer Gaslightwala effective August 18, 2026. Base salary increased to $625,000 annually (with $62,500 voluntarily converted to RSUs over 12 months); annual bonus target set at 55% of base salary. Equity grants include: 1,100,000 time-based ADS options (4-year vest, 25% cliff at 12 months), 600,000 performance-based ADS options (vesting tied to $15M+ financing or $10M+ ADC license by Dec 31, 2025—expired unmet), and 174,000 supplemental ADS options (4-year vest from March 18, 2026). All equity grants require shareholder approval of plan amendment to increase reserved shares.
Why this rating
CEO comp restructuring is material relative to $15M market cap (~4% salary cost) but heavily contingent on expired performance milestones and plan approval. Equity grants dilutive but conditional. Moderate business significance; addresses retention but signals past targets missed.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.